These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26905326)

  • 1. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
    Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
    Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
    Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P
    J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
    Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
    Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibition: past, present and future.
    Curtin NJ; Szabo C
    Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
    Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitor pick-me-up.
    Mullard A
    Nat Rev Drug Discov; 2019 Oct; 18(11):814. PubMed ID: 31673138
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory PARP w terapii raka jajnika.
    Kruczała MA; Grela-Wojewoda A; Cedrych I
    Ginekol Pol; 2016; 87(2):131-4. PubMed ID: 27306290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on Poly(ADP-ribose) Polymerase I-A Brief Review.
    Negi P; Lakshmanan K; Patel PK; Rajagopal K; Byran G
    Mini Rev Med Chem; 2023; 23(18):1762-1771. PubMed ID: 36824002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
    Chelariu-Raicu A; Zibetti Dal Molin G; Coleman RL
    Int J Gynecol Cancer; 2020 Oct; 30(10):1608-1618. PubMed ID: 32928926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
    Hottiger MO
    Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors for anticancer therapy.
    Curtin N
    Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.